BioSpace News Archive

Recently, magAssist’s NyokAssist™ Interventional Ventricular Assist Device, has been granted designation as a breakthrough device by the U.S. Food and Drug Administration in Breakthrough Device Program.

Inhalis Therapeutics SA, a pioneering privately-held company specializing in advanced inhaled treatments for life-threatening diseases, proudly reveals a significant stride forward as it submits a new patent application on INHAL-101, its lead asset.

Teleflex Incorporated, a leading global provider of medical technologies, announced the release of the Arrow™ ErgoPack™ Complete Kits with Hemodialysis and Large Bore catheters in the United States.

NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s broad-spectrum antiviral drug, is progressing successfully.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately.

Krystal Biotech, Inc. announced that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million.

GeneDx today announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx.

Tonix Pharmaceuticals today announced that it received the official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-8011 (recombinant horsepox virus, live vaccine) as a potential vaccine to protect against mpox disease (formerly known as monkeypox) and smallpox.

Willow Biosciences Inc. today announced a collaboration with a Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs).

A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing.